Patents by Inventor Geoffrey M. Wahl
Geoffrey M. Wahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120076762Abstract: Methods and compositions are provided for, inter alia, the generation of induced pluripotent stem cells. Induced pluripotent stem cells may be generated by reprogramming and inhibition of p53. Further, useful intermediates for the generation of induced pluripotent stem cells are also provided.Type: ApplicationFiled: March 24, 2010Publication date: March 29, 2012Applicant: THE SALK INSTITUTE FOR BIOLOGICAL STUDIESInventors: Teruhisa Kawamura, Jotaro Suzuki, Yunyuan V. Wang, Angel Raya, Geoffrey M. Wahl, Juan Carlos Izpisua Belmonte
-
Patent number: 7371577Abstract: A gene activation/inactivation and site-specific integration system has been developed for mammalian cells. The invention system is based on the recombination of transfected sequences by FLP, a recombinase derived from Saccharomyces. In several cell lines, FLP has been shown to rapidly and precisely recombine copies of its specific target sequence. For example, a chromosomally integrated, silent ?-galactosidase reporter gene was activated for expression by FLP-mediated removal of intervening sequences to generate clones of marked cells. Alternatively, the reverse reaction can be used to target transfected DNA to specific chromosomal sites. These results demonstrate that FLP can be used, for example, to mosaically activate or inactivate transgenes for a variety of therapeutic purposes, as well as for analysis of vertebrate development.Type: GrantFiled: July 18, 2005Date of Patent: May 13, 2008Assignee: The Salk Institute for Biological StudiesInventors: Geoffrey M. Wahl, Stephen V. O'Gorman
-
Patent number: 6956146Abstract: A gene activation/inactivation and site-specific integration system has been developed for mammalian cells. The invention system is based on the recombination of transfected sequences by FLP, a recombinase derived from Saccharomyces. In several cell lines, FLP has been shown to rapidly and precisely recombine copies of its specific target sequence. For example, a chromosomally integrated, silent ?-galactosidase reporter gene was activated for expression by FLP-mediated removal of intervening sequences to generate clones of marked cells. Alternatively, the reverse reaction can be used to target transfected DNA to specific chromosomal sites. These results demonstrate that FLP can be used, for example, to mosaically activate or inactivate transgenes for a variety of therapeutic purposes, as well as for analysis of vertebrate development.Type: GrantFiled: February 28, 2002Date of Patent: October 18, 2005Assignee: The Salk Institute for Biological StudiesInventors: Geoffrey M. Wahl, Stephen V. O'Gorman
-
Patent number: 6946259Abstract: This invention provides methods by which test substances can be screened for their ability to inhibit, enhance or eliminate double minute (DM) or extrachromosomal DNA by micronucleation in cells. This invention also provides a method for inducing maturation or death of a cell having the capacity to generate micronuclei. It also provides a method of treating a disease in a subject, the cells correlated with the disease having DM and extrachromosomal DNA as well as the capacity to generate micronuclei to capture them. Further provided is a method of detecting chromosomal and extrachromosomal DNA in a cell.Type: GrantFiled: January 12, 1999Date of Patent: September 20, 2005Assignee: The Salk Institute For Biological StudiesInventors: Geoffrey M. Wahl, Noriaki Shimizu, Teru Kanda, H. Michael Shepard
-
Publication number: 20050123909Abstract: This invention provides methods by which test substances can be screened for their ability to inhibit, enhance or eliminate double minute (DM) or extrachromosomal DNA by micronucleation in cells. This invention also provides a method for inducing maturation or death of a cell having the capacity to generate micronuclei. It also provides a method of treating a disease in a subject, the cells correlated with the disease having DM and extrachromosomal DNA as well as the capacity to generate micronuclei to capture them. Further provided is a method of detecting chromosomal and extrachromosomal DNA in a cell.Type: ApplicationFiled: January 12, 1999Publication date: June 9, 2005Inventors: GEOFFREY M. WAHL, NORIAKI SHIMIZU, TERU KANDA, H. MICHAEL SHEPARD
-
Patent number: 6537758Abstract: The present invention provides a method for isolating nucleic acid from micronuclei separated from a cell that involves separating micronuclei from a cell and isolating nucleic acid from the micronuclei.Type: GrantFiled: September 13, 2001Date of Patent: March 25, 2003Assignee: The Salk Institute for Biological StudiesInventors: Geoffrey M. Wahl, Noriaki Shimizu
-
Publication number: 20020166138Abstract: A gene activation/inactivation and site-specific integration system has been developed for mammalian cells. The invention system is based on the recombination of transfected sequences by FLP, a recombinase derived from Saccharomyces. In several cell lines, FLP has been shown to rapidly and precisely recombine copies of its specific target sequence. For example, a chromosomally integrated, silent &bgr;-galactosidase reporter gene was activated for expression by FLP-mediated removal of intervening sequences to generate clones of marked cells. Alternatively, the reverse reaction can be used to target transfected DNA to specific chromosomal sites. These results demonstrate that FLP can be used, for example, to mosaically activate or inactivate transgenes for a variety of therapeutic purposes, as well as for analysis of vertebrate development.Type: ApplicationFiled: February 28, 2002Publication date: November 7, 2002Applicant: The Salk Institute for Biological StudiesInventors: Geoffrey M. Wahl, Stephen V. O'Gorman
-
Publication number: 20020102583Abstract: The present invention provides a method for the isolation of extrachromosomal amplified nucleic acids that are associated with a cell proliferative disorder. Isolation and further identification of such genes is critical for diagnosis, prognosis, and course of therapy.Type: ApplicationFiled: September 13, 2001Publication date: August 1, 2002Applicant: The Salk Institute for Biological StudiesInventors: Geoffrey M. Wahl, Noriaki Shimizu
-
Patent number: 6312908Abstract: The present invention provides a method for the isolation of extrachromosomal amplified nucleic acids that are associated with a cell proliferative disorder. Isolation and further identification of such genes is critical for diagnosis, prognosis, and course of therapy.Type: GrantFiled: March 7, 2000Date of Patent: November 6, 2001Assignee: Salk Institute for Biological SciencesInventors: Geoffrey M. Wahl, Noriaki Shimizu
-
Patent number: 6033849Abstract: The present invention provides a method for the isolation of extrachromosomal amplified nucleic acids that are associated with a cell proliferative disorder. Isolation and further identification of such genes is critical for diagnosis, prognosis, and course of therapy.Type: GrantFiled: August 26, 1996Date of Patent: March 7, 2000Assignee: The Salk Institute for Biological StudiesInventors: Geoffrey M. Wahl, Noriaki Shimizu
-
Patent number: 5885836Abstract: A gene activation/inactivation and site-specific integration system has been developed for mammalian cells. The invention system is based on the recombination of transfected sequences by FLP, a recombinase derived from Saccharomyces. In several cell lines, FLP has been shown to rapidly and precisely recombine copies of its specific target sequence. For example, a chromosomally integrated, silent .beta.-galactosidase reporter gene was activated for expression by FLP-mediated removal of intervening sequences to generate clones of marked cells. Alternatively, the reverse reaction can be used to target transfected DNA to specific chromosomal sites. These results demonstrate that FLP can be used, for example, to mosaically activate or inactivate transgenes for a variety of therapeutic purposes, as well as for analysis of vertebriate development.Type: GrantFiled: April 8, 1997Date of Patent: March 23, 1999Assignee: The Salk Institute For Biological StudiesInventors: Geoffrey M. Wahl, Stephen V. O'Gorman
-
Patent number: 5677177Abstract: A gene activation/inactivation and site-specific integration system has been developed for mammalian cells. The invention system is based on the recombination of transfected sequences by FLP, a recombinase derived from Saccharomyces. In several cell lines, FLP has been shown to rapidly and precisely recombine copies of its specific target sequence. For example, a chromosomally integrated, silent .beta.-galactosidase reporter gene was activated for expression by FLP-mediated removal of intervening sequences to generate clones of marked cells. Alternatively, the reverse reaction can be used to target transfected DNA to specific chromosomal sites. These results demonstrate that FLP can be used, for example, to mosaically activate or inactivate transgenes for a variety of therapeutic purposes, as well as for analysis of vertebriate development.Type: GrantFiled: June 7, 1995Date of Patent: October 14, 1997Assignee: The Salk Institute for Biological StudiesInventors: Geoffrey M. Wahl, Stephen V. O'Gorman
-
Patent number: 5654182Abstract: A gene activation/inactivation and site-specific integration system has been developed for mammalian cells. The invention system is based on the recombination of transfected sequences by FLP, a recombinase derived from Saccharomyces. In several cell lines, FLP has been shown to rapidly and precisely recombine copies of its specific target sequence. For example, a chromosomally integrated, silent .beta.-galactosidase reporter gene was activated for expression by FLP-mediated removal of intervening sequences to generate clones of marked cells. Alternatively, the reverse reaction can be used to target transfected DNA to specific chromosomal sites. These results demonstrate that FLP can be used, for example, to mosaically activate or inactivate transgenes for a variety of therapeutic purposes, as well as for analysis of vertebriate development.Type: GrantFiled: June 7, 1995Date of Patent: August 5, 1997Assignee: The Salk Institute for Biological StudiesInventors: Geoffrey M. Wahl, Stephen V. O'Gorman
-
Patent number: 5130446Abstract: Fluorescent linker moieties are provided which comprise a fluorescent compound such as fluorescein attached to a linker moiety such that a functional group of the linker is available for attachment to an affinity molecule such as a nucleic acid which has an N.sup.4 (substituted amino) cytosine moiety. Probes tagged with fluorescent derivatives such as fluorescein, tetramethyrhodamine or tetraethylrhodamine may be detected by fluorescence spectroscopic methods.Type: GrantFiled: March 14, 1989Date of Patent: July 14, 1992Assignee: Siska Diagnostics, Inc.Inventors: Gary F. Musso, Soumitra Ghosh, Leslie E. Orgel, Geoffrey M. Wahl, Emil T. Kaiser
-
Patent number: 4833251Abstract: Nucleic acid hybridization probes are provided which comprise an N.sup.4 -(substituted amino)cytosine moiety, wherein the substituted amino group comprises a tag moiety, whereby the probe is detected. Methods of preparing probes of the invention, intermediates used in such methods, and methods of using the probes of the invention in hybridization assays are also provided. Typical tag moieties employed with the probes of the invention are biotinyl, aminothiadiazole and fluorescein derivatives, connected to N.sup.4 -amino groups of modified cytosines of the probe through linker moieties. Probes tagged with biotin are typically detected by binding to the biotinyl moieties, through a streptavidin or avidin molecule, a reporter group which includes streptavidin or avidin and then detecting a signal due to the reporter group.Type: GrantFiled: November 16, 1987Date of Patent: May 23, 1989Assignee: Siska Diagnostics, Inc.Inventors: Gary F. Musso, Soumitra Ghosh, Leslie E. Orgel, Geoffrey M. Wahl, Emil T. Kaiser
-
Patent number: 4780405Abstract: Nucleic acid hybridization probes are provided which comprise nucleoside bases or terminal nucleotide phosphates chemically linked to aromatic sulfonamide inhibitors of carbonic anhydrase. Methods of preparing probes of the invention, intermediates used in such methods, and methods of using the probes of the invention in hybridization assays are also provided. A probe of the invention is detected by binding to it a reporter group, such as a homopolymer or heteropolymer of enzymes, which includes a carbonic anhydrase which binds to the inhibitor linked to the probe, and then detecting the bound reporter group, as by production of a fluorescent or colored product in a reaction catalyzed by an enzyme component of the reporter group. Also provided are enzyme immunoassays wherein detection of antibody is by a process which comprises a chemical reaction catalyzed by a carbonic anhydrase.Type: GrantFiled: July 9, 1985Date of Patent: October 25, 1988Assignee: Siska Diagnostics, Inc.Inventors: Emil T. Kaiser, Gary F. Musso, Soumitra Ghosh, Leslie E. Orgel, Geoffrey M. Wahl
-
Patent number: 4302204Abstract: Improvements in the transfer and detection of separated nucleic acids, both RNA and DNA, are provided. For analysis of large DNA, the molecular weight segregated fractions of DNA are depurinated and fragmented to provide fractions having less than about 2 kb as single strands. With both RNA and DNA, the nucleic acid fractions are transferred after resolution to a chemically treated substrate and covalently affixed to the substrate. The resulting nucleotides affixed to the substrate are hybridized with labeled nucleotide probes and a volume exclusion agent, particularly a water soluble ionic polymer.Type: GrantFiled: July 2, 1979Date of Patent: November 24, 1981Assignee: The Board of Trustees of Leland Stanford Junior UniversityInventors: Geoffrey M. Wahl, George R. Stark